anxiety
ANXIETY

Anxiety disorders are disorders wherein the patient experiences uncontrollable fear or anxiety with behavioral disturbances that affects normal functioning.

Generalized anxiety disorder is having excessive anxiety and worry occurring for at least 6 months about several events or activities. The person finds it difficult to control the worry.
Panic disorder is when the person experienced recurrent unexpected panic attacks.
Social anxiety disorder is marked and persistent fear of social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others.

Drug Information

Indication: Major depressive episode, panic disorder w/ or w/o agoraphobia, social or generalized anxiety disorder, obsess...

Indication: Neuropathic pain in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisatio...

Indication: Depressive syndromes.

Indication: Symptomatic treatment of depression including depression accompanied by symptoms of anxiety in patients w/ or ...

Indication: Short-term treatment of moderate or severe anxiety & anxiety associated w/ depression.

Dosage: Anxiety Initially 0.25-0.5 mg tds. Usual dose range: 0.5-4 mg daily. Depression Initially 0.5 mg tds. Usual do

Indication: Symptomatic treatment of depression including depression accompanied by symptoms of anxiety. Obsessive compuls...

Indication: Depression & prevention of relapse/recurrence; panic disorder (PD) w/ or w/o agoraphobia; obsessive-compul...

Indication: Major depressive disorder, generalized anxiety disorder. Management of diabetic peripheral neuropathic pain.

Indication: Anxiety, acute alcohol w/drawal symptoms, pre-op procedures to relieve anxiety & tension; adjunct prior to...

1  /  8
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 3 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 4 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.